AbbVie and Gubra Collaborate to Develop Amylin Analog Targeting Obesity Treatment AbbVie and Gubra have partnered to advance GUB014295, an innovative amylin analog for obesity management, fostering potential growth and collaboration against global health challenges.

AbbVie and Gubra Collaborate to Develop Amylin Analog Targeting Obesity Treatment #United_States #AbbVie #North_Chicago #Gubra #GUB014295